SEATTLE, WASHINGTON
Biotechnology
2
$5.36M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-10-23 | New offering first sale 2026-03-25 | $2.33M | $2.50M | details · SEC filing |
| 2023-05-19 | New offering first sale 2023-05-04 | $3.03M | $5M | SEC filing |
Watch Key Proteo, Inc.
Get an email when Key Proteo, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Key Proteo, Inc.?
Who to contact
- Sihoun Hahn — Executive Officer, Director, Promoter
- Jae-Hoon Song — Director
- Koo Ja-Kyum — Director
- Round: Form D filed 2026-10-23
- Amount sold: $2.33M
- Industry: Biotechnology
- Based: SEATTLE, WASHINGTON
People listed
- Sihoun Hahn — Executive Officer, Director, Promoter
- Jae-Hoon Song — Director
- Koo Ja-Kyum — Director
- Filing: Form D filed 2026-10-23
- Amount sold: $2.33M
- Industry group: Biotechnology
- Based: SEATTLE, WASHINGTON
- Entity type: Corporation
We'll show it in your MentionFox inbox when Key Proteo, Inc. raises, hires or launches. No email unless you switch it on.
Watch Key Proteo, Inc. →Want the whole picture on Key Proteo, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Key Proteo, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Key Proteo, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from Key Proteo, Inc.'s own filings with the SEC. The people those filings name are on the team page.